Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ok ... 155000 * 0.0001 = 15.5 $
LOL
Thanks to this 9800 %, are you happy ? LOL
Hope he will finish his days in jail ... Poor Crook
Did u taste Koma Unwind ?
I tasted several times, it was very good ...
What a shame Weber is just a crook ...
I can't believe that Cotton is free ... He should pass the rest of his poor life in Jail. How is possible to steal people like that, with lies ...
Lol When you will see big volumes for several days, maybe you ll be able to consider that something is happening ...
But here 20 000 ... what a joke ...
Pure Scam
Is the pork still in Jail ? lol
I hope some friends of him brings him some Koma Unwind to relax lol
Dont forget, that OCALIVA has received approbation from FDA only because there was not other treatment for PBC. And, the doses have been reduced.
Dont forget that OCALIVA increase bad cholesterol, it means, it can increase the risk of cardiovascular issue ...
Maybe you knew Georges Michaël ...
Anyway, when you have choice to take OCALIVA with all undesire effects, or Elafibranor, what would you to take ?
What would you prefer that your doctor give you ?
For me choice is fast ... It s not only a question of money, but public health ...
Risk of cancer, increase of bad cholesterol, prurit .. only attack the Fibrosis, and not the NASH, while Fibrosis is a consequence of NASH ...
Ok, you are saying not a big deal ... We ll see that ...
FXR agonist Cancer ? This is not good for ICPT, Gilead
http://www.journal-of-hepatology.eu/article/S0168-8278(17)30062-4/pdf
Wait 0.01 - 0.02 to enforce position, wait 2 years Max to perform a 500% and sell ...
This is how to trade CBIS.
Big down as predicted ... Always the same thing with this share ...
Wait 0.02 to come back inside ..
We won't never stop to be ridiculous dear Microcaps.
When will you understand that CWRN is finished?
When will you understand that CWRN has never sold iron ?
Just listen and watch the slides ...
http://wsw.com/webcast/leerink28/gnft/index.aspx
I am not based in France.
But I am sure you have experience with Vomit, Prurit etc ...
Wow, you can only say that in response of my intervention lol
Thank you to show us your level of intelligence ...
You're a funny guy haha
While ICPT has started its phase 3 several months before Genfit, ICPT has big difficulties to recruit.
Analysts are starting to think why ICPT is late in its enrollment of patient ?
We know the side effects of OCA, maybe, it must cause trouble to prescriptors to send their patients to use Ocaliva instead of Elafibranor.
Don't forget, OCA has received approbation for PBC but, it s only because there was not any treatment for PBC.
With OCA, we have prurit, increase of bad cholesterol, the increase of cardiovascular problem ...
Also, OCA is focus on Fibrosis, and neither on NASH. Fibrosis is a consequence of NASH ... When you have Fibrosis, you are already in an advanced state of NASH.
While Elafibranor attacks NASH and Fibrosis, reduce bad cholesterol etc ...
If you were sick, what treatment will you choose ?
The enrollment of Genfit seems to be very at time.
My understanding, is that ICPT has abandoned the NASH, to focus on Fibrosis, but, it s just a symptom ...
Many analysts begin to be very sceptical about ICPT... and they are right ...
The enrollment of ICPT is a failure !
Is it time to sell CBIS and wait for a return to 0.02 ?
Huge volume here lol
+10 % Wow ...
Thanks for the feedback
Inhalers ... Can anybody buy inhalers in California ?
What is the price ? Is it really efficient ?
Haha Replace Mine by Scam ...
A much Bigger Scam you meant ...
Maybe Bob the Crook knows where is Brad the crook ?
Maybe it s a sign Dont buy
I have bought CBIS Share in 2012, for only 700 euros, while one share was at 0.14
We can see that CBIS is cyclic ... Important Up, for an important Dump.
I think, next time, that CBIS will down around 0.02, I will buy more, to hope a pump to 0.1
I think people must be cautious with this kind of PennyStock ...
Wow 100% here lol
What did happen ?
There was nothing, just a pure scam.
Our money is lost
95% of pennystocks in OTC are some scam ...
But sometimes, with luck, you can make a good percentage of gains.
But you must be ready to sell, or ,you can stay blocked for years.
I can wait, I dont need that money
I cant wait for a 300% to get back my money
There will be a justice for that fat scammer ...
Is the fat guy at slaughterhouse ?
Awesome ... So we can expect to see Brad dealing with chinese for all the tons of ore we have ... lol
Big explosion is coming lol
Fore sure it s pure bullshit ...
Years ago, I bought cans of Koma, it was very delicious, chillax ...
I dont understand how that crook has lead this company to nothing ...
What a big deception ...
There was even a provider in Belgium ...
I have ordered so much Koma Unwind ...
BW, poor crook
Prove it lol
Is the fat pork in jail ?
I am worrying about Brad ... Is still alive ? Is anyone seen him ?
Could you contact FBI ?
Isnt he lost in a mine ?
where is our money ?
I hope that Fat pork will go in jail
Stop to post old stuffs, we dont care ...
I WANT my Money BACK ... Not old PRs ...
Where is Brad ? Where is our money ?
Stop to publish those kind of information ... You never stop to manipulate people ...
I agree with you unfortunately.
Big Scam, Big Illusion, big robbery here ...
I dont understand the motivation of Microcaps to try to find good thing in CWNR
Target Price ICPT 58$
(Updated - July 6, 2016 3:11 PM EDT)
Cantor Fitzgerald initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Sell rating and a price target of $58. Analyst Elemer Piros is cautious on the company's opportunity in NASH. At most, he thinks its Phase III trial has a 25% chance to succeed.
"While Intercept just launched Ocaliva for an orphan liver disease (market potential: $700 million), we are unenthusiastic about the drug’s future in nonalcoholic steatohepatitis (NASH). We have identified six areas of weaknesses in the previous clinical package and the design of the currently ongoing Phase III trial," said Piros.
"There are ~50 million patients suffering from NASH in the U.S. and in key European countries. Untreated, 10% of patients may progress to serious liver disease, cancer or transplant. When compared to PBC, the opportunity in NASH is orders of magnitude higher. While at first glance the data supporting Ocaliva (aka OCA) in NASH appeared exciting, as more layers of the onion were peeled off, we have become less enthusiastic about its future," continued the analyst.
Piros added, "Analysis of the two Phase IIb trials (FLINT and a Japanese study) unveils significant weaknesses. First and foremost, the primary endpoint that made the FLINT trial an apparent success is not used in the ongoing Phase III trial. Individual components of the co-primary endpoints of the Phase III trial were not significant in FLINT or in the Japanese study. To make matters worse, these endpoints are now co primary. We believe that the Phase III trial has at most a 25% chance to succeed."
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $143.47 yesterday.
Which FIelD , Prurit Field ? Side Effects Field ?
For sure ... ICPT is the one player !